Is Compounded Semaglutide Still Legal in 2026? Current Status

Yes. As of 2026, compounded semaglutide is still legal in the United States, but the rules are narrower than they were during the 2023-2024 shortage. Today it's allowed mainly through patient-specific compounding, where a state-licensed pharmacy prepares it for one person because a licensed clinician has documented a clinical need for that individual. This is a fast-moving area, so the date on this page matters.

Last reviewed: . Compounding rules are changing in 2026, and some parts are still proposals rather than final law. We re-check this page roughly every 60-90 days. Treat anything here as current-as-of the review date and subject to change, and confirm your own situation with a licensed provider.

Key takeaways

• Compounded semaglutide is legal in 2026, but not the way it was during the shortage. Broad, shortage-based compounding ended; narrow, patient-specific compounding under section 503A continues where a clinician documents a clinical need for you.
• "Legal" is not the same as "FDA-approved." Compounded semaglutide is not FDA-approved, even though compounding itself is a lawful, regulated pharmacy practice.
• The shortages are over. The FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025, so "available because of a shortage" is no longer accurate.
• A proposal is pending, not final. On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B "bulks" list used by large outsourcing facilities. The FDA extended the public comment period to July 30, 2026 (a 30-day extension of the original 60-day window). It is a proposal, not a final rule.
• It's not "banned." Regulators are tightening the rules and cracking down on deceptive marketing, but patient-specific compounding with a documented clinical need remains a legal pathway as of this review date.

Is compounded semaglutide legal in 2026?

Yes, with an important caveat. Pharmacy compounding is a long-standing, lawful practice regulated under the federal Food, Drug, and Cosmetic Act. State-licensed pharmacies compound medications under section 503A, and larger "outsourcing facilities" compound under section 503B. Neither section was repealed, and neither singles out semaglutide for a ban.

What changed is how semaglutide can be compounded. During the shortage, pharmacies were broadly permitted to make copies of the drug because it was on the FDA's shortage list. That broad allowance ended when the shortage was declared resolved. What continues is the patient-specific pathway: a 503A pharmacy can prepare compounded semaglutide for an individual patient when the prescribing clinician has determined there is a genuine clinical need for a compounded version for that person, not as a mass-market copy of the brand drug.

So the honest one-line answer is: legal, but narrower, and case-by-case. Whether a compounded option is appropriate for you specifically is a decision for a licensed clinician.

Why can pharmacies still compound semaglutide if the shortage is over?

Because shortage-based compounding and patient-specific compounding are two different things.

• Shortage-based compounding was the temporary, broad permission that let compounders make copies while the FDA-approved product wasn't available. That ended with the shortage.
• Patient-specific compounding is the ordinary, everyday function of a compounding pharmacy: preparing a customized medication for an individual when a prescriber documents that a commercially available product doesn't meet that patient's needs. This pathway pre-dates the GLP-1 boom and is not tied to any shortage.

You may still see the phrase "available because of the shortage" on other sites. That framing is out of date for 2026. The shortages have been resolved for over a year, and today's compounding rests on the patient-specific pathway, not the shortage list.

What changed, and when? A 2026 timeline

Here is the sequence that took compounded GLP-1s from "widely available" to "narrower and patient-specific." This is the part most explainers skip.

Sources for each row are in the References below, all from the FDA directly.

What is the FDA's April 2026 503B proposal, and does it ban compounding?

No, it doesn't ban compounding. Here's the plain-English version.

Outsourcing facilities (503B) generally can only compound a drug from a bulk drug substance if that substance is on the FDA's 503B "bulks" list, or if the drug is on the shortage list at the time. On April 30, 2026, the FDA announced a proposal to formally exclude semaglutide, tirzepatide, and liraglutide from that bulks list, saying it did not find sufficient evidence of a clinical need for outsourcing facilities to make these drugs from bulk. The FDA opened a public comment docket and, in June 2026, extended the comment period to July 30, 2026 (a 30-day extension of the original 60-day window). It has said it will consider the comments before making a final determination.

Two things to hold onto:

1. It's a proposal, not a final rule. As of this page's review date, nothing about it is settled law, and the FDA has said it will weigh public comments first.
2. It targets the 503B bulks pathway specifically, the route large outsourcing facilities use to compound from bulk ingredients. The patient-specific 503A pathway is a separate track. That said, the overall direction of regulation is tightening, so treat the whole area as evolving and confirm current terms with a licensed provider.

Is compounded semaglutide being banned?

No, "banned" is the wrong word for what's happening. As of this review date, compounded semaglutide is not illegal and not banned. What's true is narrower and more accurate:

• The broad, shortage-era availability ended when the shortages were resolved.
• The FDA has an open proposal that would restrict one compounding pathway (503B bulks), but it isn't final.
• Regulators are enforcing against deceptive marketing of compounded GLP-1s (more on that below), not outlawing compounding itself.

The realistic 2026 picture is a tighter, more scrutinized market, not a prohibition. Because that could shift, we date this page and re-review it.

Is compounded semaglutide FDA-approved?

No. This is the single most important distinction on this page, and it's easy to blur: legal and FDA-approved are not the same thing.

Compounding is a lawful pharmacy practice, but compounded drugs do not go through the FDA's approval process the way a brand-name drug does. Only brand-name Wegovy and Zepbound are FDA-approved for chronic weight management. (Brand Ozempic and Mounjaro contain the same molecules, semaglutide and tirzepatide, respectively, but are FDA-approved for type 2 diabetes; using them for weight loss is off-label.) Compounded versions are none of these.

About compounded medications: Compounded semaglutide and tirzepatide are prepared by a

state-licensed compounding pharmacy and prescribed by a licensed clinician when appropriate for you.

**Compounded medications are not FDA-approved and are not reviewed by the FDA for safety,

effectiveness, or quality.** They are not "generic" versions of Ozempic®, Wegovy®, Mounjaro®, or

Zepbound®. Talk to a licensed clinician about whether a compounded or FDA-approved option is right for you.

The FDA has also flagged real safety concerns with unapproved and compounded GLP-1s, including dosing errors from multi-dose vials, use of unapproved salt forms of the active ingredient, and products arriving without proper refrigeration. That's not a reason to panic; it's a reason to be selective about where you get care.

Is compounded tirzepatide legal too?

Yes, the situation is essentially the same for tirzepatide. Its shortage was declared resolved slightly earlier (December 19, 2024), broad shortage-based compounding wound down in 2025, and tirzepatide is included in the same April 2026 503B bulks proposal as semaglutide. So the same summary applies: legal in 2026 through the patient-specific pathway, not FDA-approved, and subject to a pending proposal that isn't final. If you're weighing this molecule specifically, our tirzepatide for women guide covers how it works and how Elara provides it.

What this means for you as a patient

The regulatory tightening is really about pushing the market toward legitimate, clinician-supervised care and away from sketchy sellers. The FTC underscored that in December 2025, when it finalized an order against telehealth GLP-1 seller NextMed over undisclosed costs, hidden membership commitments, unsupported weight-loss claims, and fake testimonials.

So the practical question isn't only "is it legal?", it's "am I getting it the right way?" Signs of legitimate care:

• A licensed provider reviews every patient before prescribing (synchronously or asynchronously depending on your state).
• The medication comes from a US state-licensed pharmacy, not an overseas or "research use only" seller.
• Transparent, all-in pricing with no surprise fees.
• Clear safety information and real human support.

Walk away from "no prescription needed," "research chemical" labeling, miracle promises, or prices that balloon after you pay. For a deeper checklist, see is it safe to get semaglutide online.

Safety note. Semaglutide and tirzepatide carry a boxed warning for the risk of thyroid C-cell tumors. They are contraindicated if you or a family member have had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Other important cautions include pancreatitis, gallbladder problems, and significant gastrointestinal side effects. GLP-1s are not recommended in pregnancy or while breastfeeding. This is not the full list, review the FDA prescribing information and talk to a licensed provider about what's right for you.

How Elara helps

Elara offers compounded semaglutide and tirzepatide the way regulators say it should be done: a licensed provider reviews every patient, the medication is prepared by a state-licensed compounding pharmacy, and pricing is transparent and all-inclusive, the visit, the medication, shipping, and ongoing support, with no separate membership fee. Elara serves all 50 states plus Puerto Rico, is cash-pay (no insurance hurdles), and offers 7-day-a-week human support. Because the rules are moving, Elara's clinical team follows FDA guidance closely.

**Explore Elara's compounded semaglutide program, from $247/month, all-in, or take the free eligibility check; a licensed provider reviews every patient. Compounded medications are not FDA-approved.**

To go deeper on the money side, compare the real numbers in our semaglutide cost breakdown and tirzepatide cost breakdown.

Frequently asked questions

Is compounded semaglutide legal in 2026? Yes, as of this page's review date. Compounding is a lawful, regulated pharmacy practice, and compounded semaglutide remains legal through the patient-specific pathway under section 503A, where a licensed clinician documents a clinical need for you individually. The broad, shortage-based availability of 2023-2024 has ended.

Is compounded semaglutide being banned? No. It is not banned or illegal as of this review date. The FDA has an open proposal (from April 30, 2026) that would restrict one compounding route, the 503B bulks list used by large outsourcing facilities, but that proposal is not final. Regulators are tightening rules and targeting deceptive marketing, not prohibiting compounding.

Is compounded semaglutide FDA-approved? No. Legal and FDA-approved are different things. Compounded semaglutide is not FDA-approved and is not reviewed by the FDA for safety, effectiveness, or quality. Only brand-name Wegovy and Zepbound are FDA-approved for chronic weight management. Talk to a licensed provider about which option fits your situation.

Why can pharmacies still compound semaglutide if the shortage ended? Because patient-specific compounding is separate from shortage-based compounding. Preparing a customized medication for one patient, when a prescriber documents that a commercially available product doesn't meet that person's needs, is an ordinary, long-standing pharmacy function that doesn't depend on a shortage. That pathway continued after the shortage was resolved.

Is compounded tirzepatide legal too? Yes, essentially the same rules apply. The tirzepatide shortage was declared resolved on December 19, 2024, broad shortage-based compounding wound down in 2025, and tirzepatide is part of the same April 2026 503B bulks proposal as semaglutide. It remains legal through the patient-specific pathway, is not FDA-approved, and is subject to that pending, non-final proposal.

The bottom line

Compounded semaglutide is still legal in 2026, but under narrower, patient-specific rules than during the shortage, and "legal" does not mean "FDA-approved." A proposal to restrict one compounding pathway is pending but not final, so the picture may shift. Because this is a fast-moving area, treat this page as current as of its review date, and talk to a licensed provider about what's appropriate for you.

References

1. U.S. Food & Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
2. U.S. Food & Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (Apr. 30, 2026). https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
3. Federal Register. List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B … ; Extension of Comment Period (91 FR 38719, June 26, 2026; Docket No. FDA-2018-N-3240), extends the comment period to July 30, 2026. https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
4. U.S. Food & Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
5. Federal Trade Commission. FTC Approves Final Order Against Telehealth Provider NextMed Over Charges It Used Deceptive Advertising Claims to Sell GLP-1 Weight-Loss Programs (Dec. 3, 2025). https://www.ftc.gov/news-events/news/press-releases/2025/12/ftc-approves-final-order-against-telehealth-provider-nextmed-over-charges-it-used-deceptive
6. U.S. Food & Drug Administration / DailyMed. Wegovy (semaglutide) Prescribing Information, Boxed Warning: Risk of Thyroid C-Cell Tumors. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

This article is for general education and is not medical advice. Talk to a licensed clinician about your situation.

Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality.